Advances in antibody-based therapy in oncology

Sacha Zinn; Rodrigo Vazquez-Lombardi; Carsten Zimmermann; Puja Sapra; Lutz Jermutus; Daniel Christ

doi:10.1038/s43018-023-00516-z

Advances in antibody-based therapy in oncology

Nat Cancer. 2023 Feb;4(2):165-180. doi: 10.1038/s43018-023-00516-z. Epub 2023 Feb 20.

Authors

Sacha Zinn^{1

2}, Rodrigo Vazquez-Lombardi^{1

2

3}, Carsten Zimmermann^{4

5}, Puja Sapra⁶, Lutz Jermutus⁷, Daniel Christ^{8

9}

Affiliations

¹ Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
² Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia.
³ Engimmune Therapeutics, Allschwil, Switzerland.
⁴ University of San Diego, Knauss School of Business, San Diego, CA, USA.
⁵ University of California San Diego, La Jolla, CA, USA.
⁶ AstraZeneca, Oncology R&D, Biologics Engineering & Targeted Delivery, Gaithersburg, MD, USA.
⁷ AstraZeneca, BioPharmaceuticals R&D, Research & Early Development, Cambridge, UK.
⁸ Garvan Institute of Medical Research, Sydney, New South Wales, Australia. [email protected].
⁹ Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia. [email protected].

PMID: 36806801
DOI: 10.1038/s43018-023-00516-z

Abstract

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discuss molecular structure and mechanisms of action and provide updates on clinical development and practice.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal* / pharmacology
Antibodies, Monoclonal* / therapeutic use
Humans
Neoplasms* / drug therapy
Radioimmunotherapy

Substances

Antibodies, Monoclonal